Albany NY, United States: Cholinesterase inhibitors, also known as acetylcholine inhibitors, are a group of drugs that are used to prevent the routine breakdown of acetylcholine in the body
Albany NY, United States: Cholinesterase inhibitors, also known as acetylcholine inhibitors, are a group of drugs that are used to prevent the routine breakdown of acetylcholine in the body
Acetylcholine is one of the key neurotransmitters in the body that is functional in central as well as the peripheral nervous system. Acetylcholine levels have an effect on learning, thinking, memory, and cognitive functions of the body. Low level of acetylcholine in the body adversely affects the memory and cognitive functions, especially in patients with dementia.
Read Report Overview - https://www.transparencymarketresearch.com/cholinesterase-inhibitors-market.html
Cholinesterase inhibitors inactivate the acetylcholine’s neurotransmission activity by preventing it from routine breakdown. This leads to an increase in the levels of acetylcholine in the body.
Cholinesterase inhibitors are primarily used in the treatment of dementia caused due to Alzheimer’s disease. These drugs are also prescribed for the treatment of Lewy body dementia, Parkinson’s disease, glaucoma, myasthenia gravis, and schizophrenia.
Cholinesterase Inhibitors Market: Key Drivers
- High prevalence and rise in incidence rate of dementia caused due to Alzheimer’s and Parkinson’s diseases across the globe is one of the factors expected to drive the global cholinesterase inhibitors market during the forecast period
- According to the World Health Organization, around 50 million people across the globe are afflicted with dementia and around 10 million new people are diagnosed with dementia every year
- New product development and commercialization and large number of promising drugs in different stages of clinical pipeline studies are key factors anticipated to propel the market during the forecast period
- Rapidly aging population in developed countries is also likely to drive the market in the near future
- On the other hand, availability of alternative therapeutic drugs for the treatment of dementia caused due to Alzheimer’s and Parkinson’s diseases; and side-effects of cholinesterase inhibitors are estimated to restrain the market during the forecast period
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78382
Alzheimer’s Disease Indication Segment to be Highly Attractive
- In terms of indication, the global market can be segmented into Alzheimer’s disease caused dementia, Parkinson’s disease caused dementia, Lewy body dementia, schizophrenia, myasthenia gravis, and others. The Alzheimer’s disease caused dementia segment is estimated to dominate the market during the forecast period.
- Alzheimer’s disease accounts for 60%-80% share of the total dementia cases diagnosed worldwide
Intravenous Route of Administration Segment to Dominate Global Market
- In terms of route of administration, the global cholinesterase inhibitors market can be classified into oral route, intravenous route, intramuscular route, and transdermal route. The intravenous route segment is projected to dominate the global market during the forecast period.
- High bioavailability of drugs through intravenous route and high cost of IV cholinesterase inhibitors are factors that are estimated to contribute to leading share of the segment. Furthermore, intravenous is a commonly prescribed route of administration. This is another factor projected to augment the segment.
Request for Analysis of COVID-19 Impact on Cholinesterase Inhibitors Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78382
Retail Pharmacies Distribution Channel to be Highly Lucrative Segment
- Based on distribution channel, the global cholinesterase inhibitors market can be segregated into hospital pharmacies, retail pharmacies, and e-commerce. The retail pharmacies segment is projected to dominate the global market during the forecast period.
- Presence of large numbers of retail pharmacy stores, easy availability and accessibility of cholinesterase inhibitors at these stores, and low cost are factors that are estimated to drive the retail pharmacies segment in the near future
Asia Pacific Cholinesterase Inhibitors Market to Expand Rapidly
- In terms of region, the global cholinesterase inhibitors market can be split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America is expected to dominate the global market during the forecast period. High prevalence of dementia, Alzheimer’s disease, and Parkinson’s disease; and rise in aging population are factors anticipated to boost the market in the region during the forecast period. According to the U.S.-based Alzheimer’s Association, around 5.2 million people in the country were suffering from Alzheimer’s disease induced dementia in 2019
- The cholinesterase inhibitors market in Asia Pacific is anticipated to expand at a fast-paced CAGR during the forecast period. Rapid growth of the market in Asia Pacific can be ascribed to increase in number of hospitals and ambulatory surgery centers, high prevalence of Alzheimer’s disease in densely populated countries such as India and China, and improvement in health care infrastructure in the region.
- High growth rate of the health care industry, easy access to health care facilities, and increase in investments in health care by leading players in Asia Pacific are also expected to fuel the market in the region in the near future
Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=78382
Key Players Operating in Global Cholinesterase Inhibitors Market
The global cholinesterase inhibitors market is fragmented, with large number of global players holding major share. Key players operating in the global cholinesterase inhibitors market include:
- Sciele Pharm, Inc.
- Janssen Pharmaceutical Inc.
- Allergan Plc.
- Adamas Pharmaceutical inc.
- Eisai Co., Ltd.
- Novartis AG
- Sanofi-Aventis U.S. LLC
- Avadel Pharmaceuticals
- Teva Pharmaceutical Industries Limited.
Browse more Reports by Transparency Market Research:
Medical Image Analysis Software Market: Increase in the incidence of chronic diseases, rise in geriatric population, increase in the adoption of 4D imaging techniques, and rise in demand for medical imaging are projected to drive the global medical image analysis software market during the forecast period.s
Veterinary Molecular Diagnostics Market: Increase in companion animal ownership is a trend witnessed in the animal healthcare segment. Spending capacity on companion animals is also on the rise. Rise in obesity among pets and increase in awareness about veterinary diagnostics are projected to drive the global veterinary molecular diagnostics market during the forecast period.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453